Reforgene again named a Guangzhou Future Unicorn enterprise
Recently, the 2023 Guangzhou International Innovation Festival was grandly held at the Guangzhou Library. At the opening ceremony of the conference, the highly anticipated unicorn innovative enterprise list was officially unveiled. Reforgene was successfully selected as a "Future Unicorn Innovative Enterprise", its second consecutive year receiving this honor.
The 2023 Guangzhou Unicorn innovative enterprise list is an authoritative list guided by the Guangzhou Municipal Science and Technology Bureau and jointly hosted and released by the Guangzhou Industrial Development Research Institute, the Guangzhou Science and Technology Innovation Enterprises Association and PwC China, aiming to identify innovative enterprises with strong innovation, fast growth and great development potential, cultivate future leading innovative enterprises, and give play to their innovation-leading and demonstration roles.
In recent years, cell and gene therapy has developed rapidly and has become one of the most promising directions in the biomedical field. Reforgene is dedicated to the development of innovative gene editing medicines. With its continuously deepening underlying technology innovation capability and excellent talent team, it has pipeline programs in hematology, ophthalmology, liver and central nervous system fields, achieving notable progress.
Recently, Reforgene announced that its independently developed beta-thalassemia gene editing medicine RM001 (HBG gene-modified autologous CD34+ hematopoietic stem cell injection) has achieved leading excellent efficacy, with Phase I clinical trials nearing completion and Phase II clinical trials planned for 2024.
Being listed again as a "Future Unicorn Innovative Enterprise" is both an honor and an encouragement. Reforgene will not forget its original aspiration and will forge ahead, upholding the mission of "Innovation for Life", deeply cultivating underlying gene editing technology and drug R&D, and dedicating itself to developing curative medicines for serious diseases, so that cutting-edge biotechnology benefits human health.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.